Know What's Happening in BioTech
Know What's Happening in BioTech
BioTech Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
Scientists at the University of Padova synthesized fluorinated psilocin derivatives, identifying compound 4e as a lead that retains serotonergic activity while markedly reducing hallucinogenic effects in mice. In vitro assays showed 4e is a selective partial agonist at 5‑HT2A and 5‑HT2C receptors, and pharmacokinetic studies demonstrated rapid oral absorption and brain entry. Behavioral testing revealed a muted head‑twitch response compared with psilocybin, suggesting lower psychedelic potency. The work proposes a pathway to develop non‑psychoactive psychedelic medicines for neuropsychiatric disorders.
Researchers at China’s Shenyang Institute of Automation have created magnetically controlled microrobots from diatom frustules for glioblastoma photodynamic therapy. The robots retain natural chlorophyll, serving as a built‑in photosensitizer, and can be steered via external magnetic fields to tumor sites....
The Stanley Family Foundation has renewed its support for the Stanley Center for Psychiatric Research at the Broad Institute, bringing its cumulative investment to over $1 billion, including a fresh $280 million pledge. The funding fuels large‑scale genetic studies aimed at uncovering...
Lawrence Livermore National Laboratory and partners applied causal‑inference machine learning to electronic health records of more than 11,000 U.S. veterans with amyotrophic lateral sclerosis. The analysis, published in The Lancet Digital Health, identified 27 existing medications that correlate with longer...
Researchers have identified a streamlined DNA construct that could replace viral carriers in gene‑therapy applications. The study demonstrates that this minimalist DNA format delivers therapeutic genes with efficiency comparable to adeno‑associated viruses while eliciting a weaker immune response. Production of...
The FDA launched the Adverse Event Monitoring System (AEMS), a unified dashboard that merges seven previously fragmented safety databases into a single platform. Four databases are already live, with the remaining three slated for integration by May, covering drugs, vaccines,...
The FDA has launched the Adverse Event Monitoring System (AEMS), a unified platform that merges seven previously fragmented safety‑surveillance databases. Four of those databases are live today, with the remaining three slated for integration by May 2026. The agency processes...
Vena Medical secured FDA clearance for its Vena MicroAngioscope System, marketed as the world’s smallest intravascular camera, for peripheral artery imaging. The device provides real‑time color images without X‑ray fluoroscopy by pairing a balloon distal access catheter with a saline...
Industry experts highlight three intersecting forces reshaping emerging biotech: the persistent funding and regulatory hurdles faced by early‑stage startups, the rapid migration of AI from a supportive tool to an operational backbone, and breakthrough computational methods—including quantum chemistry—that are redefining...
The World Health Organization issued a formal warning on 13 February 2026 about a proposed randomized trial in Guinea‑Bissau that would withhold the hepatitis B birth‑dose vaccine from roughly half of 14,000 newborns. The study seeks to measure non‑specific effects...
RFK Jr is trying to get 14 peptides, without data on safety or efficacy, licensed and approved by FDA. His favorite is BPC-157. "Only three small human studies of BPC-157 exist, for instance, the largest of which is a telephone...
Lilly warns GLP-1 knockoffs may be ‘dangerous,’ escalating war with compounders https://t.co/XOKLqIzAES @ByJonGardner $LLY $NVO #obesity
Researchers discovered that the Agouti gene acts as a molecular switch governing paternal behavior in African striped mice. Males housed together displayed aggression toward pups, while solitary males became attentive fathers, a shift linked to reduced Agouti activity in the...
What is the significance of microbes in tumors, a field mired in controversy? https://t.co/D5sHkLLsrT https://t.co/ntGLlke4iC
8 Resources to study Transcription factor binding, enhancers and histone modification distribution 1. ENCODE https://t.co/N5hScyoAoP
Baseimmune announced a new fibrosis‑focused pipeline leveraging its computational protein design platform to create multi‑pathway immunotherapies, starting with idiopathic pulmonary fibrosis (IPF). The company aims to deliver proof‑of‑concept efficacy data for its lead IPF program in 2026‑2027, addressing the limitations...
Tropic, a British gene-editing startup, has raised $105 million in new financing to expand production of bananas that don’t brown https://t.co/rHHAMO6mST
AI is reshaping clinical trial oversight by moving from periodic checks to continuous, real‑time intelligence. Advanced analytics and machine learning now power predictive, risk‑based monitoring that aggregates data from decentralized sites, wearables, ePROs and multiple clinical systems. This integration enables...
Compass Pathways plc announced that its senior management will attend the Stifel 2026 Virtual CNS Forum on March 17‑18, 2026, and will take part in a fireside chat on March 18 at 10:30 am ET. The session will be streamed live...
/https://tf-cmsv2-smithsonianmag-media.s3.amazonaws.com/filer_public/6f/6f/6f6fdcf4-2eb5-46b7-bbae-350f4e5da15b/smithmag-podcast-s04-ep23-snake_venom-article.jpg)
Snakebite envenoming kills over 125,000 people each year and leaves three times as many disabled, while current horse‑derived antivenoms trigger severe allergic reactions in nearly half of patients. The high cost—up to $100,000 per course—and limited hospital access leave rural...
BridgeBio Pharma reported that its small‑molecule candidate BBP‑418 produced a 1.8‑fold increase in the α‑dystroglycan biomarker in a Phase 3 FORTIFY trial for limb‑girdle muscular dystrophy type 2I/R9, with effects sustained through 12 months. The trial enrolled 81 patients and also showed...
Aplagon Therapeutics has administered the first dose of its intravenous APAC candidate to a patient in a Phase 2a (HEALING) trial for peripheral arterial occlusive disease leading to chronic limb‑threatening ischemia in Finland. The study will enroll approximately 42 CLTI...
Pierre Fabre and $ATRA said FDA meeting to discuss the Ebvallo CRL has been scheduled. (Likely occuring within the next month.)
Jacobs and colleagues present a state‑of‑the‑art review of psilocybin and MDMA‑assisted therapies, highlighting their potential for treatment‑resistant depression and PTSD. The authors emphasize the distinct, session‑based paradigm that leverages acute neurobiological changes to produce lasting clinical benefits. However, they also...
The FDA issued draft guidance that could lower biosimilar testing requirements by permitting foreign comparator data, potentially cutting development costs by about half. Over 80 biosimilars have been approved in the U.S. since the first approval 11 years ago, yet...
The FDA is targeting telehealth marketing of GLP-1 drugs. Who’s prescribing them? Medical groups face ‘tricky’ questions when partners make misleading claims via @KatieMPalmer https://t.co/pf4Fwa7W7r
Bavarian Nordic has signed a manufacturing agreement with the Serum Institute of India to transfer full technology for its chikungunya vaccine, CHIKV VLP (branded Vimkunya). The deal replaces an earlier partnership with Biological E and builds on the companies' existing mpox‑vaccine collaboration....
Researchers at Umeå University have unveiled a capsule‑based platform that encapsulates individual cells in semi‑permeable shells, enabling multiple, sequential molecular assays on the same cell. The design permits small reagents to diffuse in while retaining DNA and RNA, and it...
GLP‑1 drugs such as semaglutide have surged from diabetes treatment to a mass‑market weight‑loss solution, with roughly 12.4% of Americans now using them. Global sales are projected to climb from $50‑60 billion today to over $135 billion within a decade, driven largely...
The FDA unveiled the Adverse Event Monitoring System (AEMS), a unified platform that shifts drug safety surveillance from quarterly updates to real‑time reporting and is expected to save roughly $120 million over five years. Simultaneously, a direct‑to‑employer drug‑purchasing model is gaining...
Eli Lilly warned that compounded versions of its GLP‑1 drugs Mounjaro and Zepbound, when mixed with vitamin B12, may contain unsafe impurities. The alert follows growing off‑label compounding as demand outpaces supply. Lilly’s notice urges clinicians and patients to verify product sources...
The FDA announced that a single pivotal trial can now satisfy efficacy requirements for new drug applications, replacing the previous two‑study mandate. This change raises expectations for data depth, quality, and risk‑based management throughout the trial lifecycle. Guests Oxana Iliach...
Dr. Steven Quay, CEO of Atossa Therapeutics, highlighted a new focus on tolerability and prevention in estrogen‑receptor‑positive breast cancer, where five‑year survival now exceeds 90%. Atossa is developing a next‑generation SERM that aims to reduce side‑effects while maintaining efficacy and...
Researchers have introduced INSITE, an injectable platform that combines primary human hepatocytes with hydrogel microspheres to form self‑assembling, vascularizable tissue ensembles in situ. Using ultrasound guidance, the scaffold is delivered to an ectopic site where it integrates with host vasculature...
Researchers introduced FAST‑CRISPR, a lipid‑silica hybrid nanoparticle that fuses directly with cell membranes to deliver CRISPR/Cas9 ribonucleoproteins. By combining a 1:1 weight ratio of cationic DOTAP and ionizable DODMA lipids with large‑pore silica cores, the platform achieves high RNP loading...
Researchers at UNIST and collaborators introduced FAST‑CRISPR, a lipid‑silica hybrid nanoparticle system designed to ferry CRISPR/Cas9 ribonucleoproteins into cells. The platform leverages a fusogenic lipid coating that promotes rapid endosomal escape, securing high‑efficiency genome editing while preserving RNP integrity. Preclinical...
GSK has pledged £11 million to launch the Modelling‑Informed Medicine Centre (MiMeC), a joint venture with Imperial College London and the University of Oxford. The centre will develop digital twins—computer‑based replicas of lungs, liver and kidneys—to run in‑silico experiments and speed...
A new longitudinal study finds that children born to mothers infected with COVID-19 during pregnancy exhibit measurable neurodevelopmental deficits. Brain scans at two years reveal reduced cortical thickness and lower IQ scores compared with unexposed peers. The research, spanning over...
Researchers are expanding CAR‑T cell therapy beyond cancer to treat autoimmune diseases such as lupus and rheumatoid arthritis. Sail Biomedicine’s chief products and operations officer highlighted on the Pharmaceutical Executive podcast that the company has pivoted to RNA‑based CAR‑T platforms,...
A randomized controlled trial of 119 infants showed that daily supplementation with Bifidobacterium infantis YLGB‑1496 for 12 weeks markedly improved gastrointestinal health, reducing stomach aches, diarrhea episodes, and related clinic visits. The probiotic also sustained higher fecal sIgA levels and...
George Medicines has signed an exclusive licensing and supply agreement with South Korea’s Ahngook Pharmaceutical to bring its triple‑combination antihypertensive pill, GMRx2, to the Korean market. The single‑pill formulation blends telmisartan, amlodipine and indapamide in three dose strengths, aiming for...
Researchers have developed a protein misfolding cyclic amplification (PMCA) assay that reliably produces recombinant prion fibrils with infectivity comparable to the RML brain‑derived strain. Cryo‑EM analysis shows these fibrils adopt the characteristic V‑shaped, parallel in‑register β‑sheet architecture, though the C‑terminal...
C2N Diagnostics has signed a partnership with BeauBrain Healthcare to introduce its PrecivityAD2 blood test for Alzheimer’s disease in South Korea, targeting patients aged 50 and older with mild cognitive impairment or dementia. Clinical studies published in JAMA and npj...
Researchers have created a New Zealand rabbit model that mimics biliary stenting by using a transduodenal wall puncture and a modified intravenous catheter. The experimental group achieved an 86.7% technical success rate, with most complications being mild and transient. Serum liver...
If you are curious about seeing what may be the last competent FDA advisory committee left standing in action as they contribute to determining access to flu shots next fall, join me, @jessicamalaty, & @SaveAmericaMvm at 12:30 pm ET on...
Mushroom mycologist Paul Stamets presented data indicating that Agarikon (Fomitopsis officinalis) mycelium possesses broad antiviral properties. In two placebo‑controlled trials, a combined Agarikon‑turkey‑tail extract reduced COVID‑19 vaccine side effects, sustained antibody titers, and accelerated recovery in hospitalized patients. The research,...
Gut Microbiota Manipulation by Probiotic Lacticaseibacillus paracasei DG I1572 as New Therapeutical Strategy to Counteract Vascular Inflammaging https://t.co/91dumlTNgU https://t.co/tkL0m8P6nd
The FDA has opened a public docket to solicit comments on its long‑standing Scale‑Up and Post‑Approval Changes (SUPAC) guidances for immediate‑release solid oral, non‑sterile semisolid, modified‑release solid oral dosage forms and the manufacturing equipment addendum. The agency seeks feedback on...
New tissue models could help researchers develop drugs for liver disease by Anne Trafton @MIT Learn more: https://t.co/hkeRZ0W47B #HealthTech #EmergingTech #TechForGood #Innovation https://t.co/LNvft8iX9M
Niclosamide extends health span and reduces frailty by ameliorating mTORC1 hyperactivation in aging models https://t.co/U8LALaiz9D https://t.co/67rsM0g0pP
